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Background: Insulin secretion is enhanced upon the binding of Glucagon-like peptide-1 (GLP-1) to its receptor
(GLP1R) in pancreatic β cells. Although a reduced expression of GLP1R in pancreatic islets from type 2 diabetic
patients and hyperglycaemic rats has been established, it is still unknown if this is caused by differential DNA
methylation of GLP1R in pancreatic islets of type 2 diabetic patients.
Methods: In this study, DNA methylation levels of 12 CpG sites close to the transcription start site of GLP1R were
analysed in pancreatic islets from 55 non-diabetic and 10 type 2 diabetic human donors as well as in β and α cells
isolated from human pancreatic islets. DNA methylation of GLP1R was related to GLP1R expression, HbA1c levels and
BMI. Moreover, mRNA expression of MECP2, DNMT1, DNMT3A and DNMT3B was analysed in pancreatic islets of the
non-diabetic and type 2 diabetic donors.
Results: One CpG unit, at position +199 and +205 bp from the transcription start site, showed a small increase in
DNA methylation in islets from donors with type 2 diabetes compared to non-diabetic donors (0.53%, p=0.02).
Furthermore, DNA methylation levels of one CpG site located 376 bp upstream of the transcription start site of
GLP1R correlated negatively with GLP1R expression (rho=−0.34, p=0.008) but positively with BMI and HbA1c
(rho=0.30, p=0.02 and rho=0.30, p=0.03, respectively). This specific CpG site is located in an area with known SP1
and SP3 transcription factor binding sites. Moreover, when we compared the DNA methylation of the GLP1R
promoter in isolated human β and α cells, we found that it was higher in α- compared with β-cells (p=0.009).
Finally, there was a trend towards decreased DNMT3A expression (p=0.056) in type 2 diabetic compared with
non-diabetic islets.
Conclusions: Together, our study shows that while BMI and HbA1c are positively associated with DNA methylation
levels of GLP1R, its expression is negatively associated with DNA methylation of GLP1R in human pancreatic islets.
Keywords: DNA methylation, Epigenetics, Glucagon-like peptide 1 receptor, GLP1R, Type 2 diabetes, Pancreatic islet,
α cells, β cells, DNMT1, DNMT3Background
Glucagon-like peptide-1 (GLP-1) is an incretin hormone
that is secreted by gastrointestinal L-cells in response to
meal intake. The peptide is produced by the posttransla-
tional modification of proglucagon [1]. The glucagon-like
peptide-1 receptor (GLP1R) is a G protein-coupled recep-
tor, which is expressed in the pancreas, lungs, heart, kid-
ney, stomach, and brain [1-4]. When GLP-1 binds to its
receptor in pancreatic β cells, an intracellular signalling
cascade is initiated, resulting in the activation of adenylate* Correspondence: charlotte.ling@med.lu.se
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reproduction in any medium, provided the orcyclase and the formation of cAMP. The increase in cAMP
enhances the secretion of insulin, providing a mechanism
for GLP-1 to regulate insulin secretion in humans. Further-
more, while several studies have shown that GLP1R is
expressed in pancreatic β cells, its expression is low or ab-
sent in pancreatic α cells [5,6].
Type 2 diabetes is a multifactorial polygenic disease
characterised by chronic hyperglycaemia due to impaired
insulin secretion and action. Dissecting the mechanisms
that contribute to insufficient insulin secretion in type 2
diabetes patients is an important goal of understanding the
disease. Disease susceptibility is affected by genetic and
non-genetic factors and a combination thereof. However,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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modifications, also participate in type 2 diabetes [7]. Indeed,
our group has previously demonstrated that DNA methyla-
tion correlates negatively with type 2 diabetes candidate
gene expression in human pancreatic islets and skeletal
muscle [7-12]. Increased DNA methylation and decreased
expression of PPARGC1A, INS and PDX1 in pancreatic is-
lets of type 2 diabetic patients is further associated with de-
creased insulin secretion [8,11,13]. However, knowledge
about the role of epigenetic mechanisms in the growing
incidence of type 2 diabetes is still limited and additional
studies analysing epigenetics in humans are hence needed.
Interestingly, GLP1R expression is decreased in pancre-
atic islets from patients with type 2 diabetes and hypergly-
caemic rats [14-16]. Although the GLP1R promoter is GC
rich and cytosine-residues in CG-dinucleotides are targets
for DNA methylation, no previous study has analysed DNA
methylation of the GLP1R promoter in human pancreatic
islets. The aim of this study was therefore to analyse the
levels of DNA methylation of the GLP1R promoter in hu-
man pancreatic islets from 55 non-diabetic organ donors
and 10 donors with type 2 diabetes. DNA methylation of
GLP1R was further correlated to gene expression, HbA1c
levels and BMI. We also tested if genes coding for proteins
involved in epigenetic processes are differentially expressed
in pancreatic islets from patients with type 2 diabetes com-
pared with non-diabetic donors.
Methods
Pancreatic islets
Pancreatic islets from 55 non-diabetic and 10 type 2 diabetic
deceased organ donors were obtained from the Human Tis-
sue Laboratory at Lund University Diabetes Centre (Table 1).
Islets were prepared by collagenase digestion and density
gradient purification. After isolation, islets were cultured free
floating in CMRL 1066 culture medium (ICN Biomedicals,
Costa Mesa, CA, USA) supplemented with 10 mmol/l HEPES,
2 mmol/l l-glutamine, 50 μg/ml gentamicin, 0.25 μg/ml
Fungizone (GIBCO, BRL, Gaithersburg, MD, USA), 20 μg/ml
ciprofloxacin (Bayer Healthcare, Leverkusen, Germany), and
10 mmol/l nicotinamide at 37°C (5% CO2) prior to RNA and
DNA preparation. Glucose-stimulated insulin release fromTable 1 Characteristics of human pancreatic donors
Phenotypes Non-diabetic
n (male/female) 55 (29/26)
Age (years) 56.7 ± 9.8
BMI (kg/m2) 25.9 ± 3.6
HbA1c 5.7 ± 0.8
Basal insulin secretion (ng/islet/h) 0.37 ± 0.27
Glucose-stimulated insulin secretion (ng/islet/h) 1.42 ± 0.95
Stimulation index 8.57 ± 9.62
Data are expressed as mean ± SD.the human islets was measured in duplicate during dynamic
glucose perifusion (Brandel, London, UK) in order to calcu-
late the stimulation index (SI), which was defined as the ra-
tio between the areas under the curves that were calculated
for the low (1.67 mM) and high (16.7 mM) glucose con-
centrations as previously described [17]. The donor before
death or her/his relatives upon admission to Intensive Care
Unit (ICU) had given their consent to donate organs and
the local ethics committees approved the protocols.Gene expression
Total RNA was isolated with the AllPrep DNA/RNA Mini
Kit (Qiagen GmbH, Hilden, Germany). RNA quality and
concentration was measured using an Agilent 2100
bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA,
USA) and Nanodrop ND-1000 equipment (NanoDrop
Technologies, Wilmington, DE), respectively. Gene expres-
sion was analysed using the Human Gene 1.0 ST Array
(Affymetrix, Santa Clara, CA, USA) analysis following
the Affymetrix standard protocol. The array data was
summarised and normalised with Robust Multi-array
Analysis (RMA) method using the software “Expression
Console” (Affymetrix).β and α cell purification
β and α cells were purified from pancreatic islets of three
human donors (aged 54, 55 and 74 years old, with BMI
21.5-23.1 kg/m2), different from the donors described in
Table 1, using a method previously described [18,19]. In
short, dissociation of islet cells was achieved by incubation
with constant agitation for 3 minutes at 37°C in 0.05 %
trypsin-EDTA (Life Technologies Ltd, Paisley, UK)
supplemented with 3 mg/ml DNAse I (Roche, Basel,
Switzerland) followed by vigorous pipetting. Labelling and
FACS sorting of the β- and α-cell fractions was performed
as previously described [19]. Sorted α and β-cells were ap-
plied to microscope slides and co-immunostained for insulin
and glucagon in order to detect the amount of α-cells in
the β-cell fraction, and vice versa. Using this method, a
β-cell purity of 89 ± 9 (mean ± SD) was achieved [19].donors Type 2 diabetes donors p-value
10 (6/4)
57.8 ± 12.6 0.74
28.1 ± 4.6 0.17
7.1 ± 1.2 0.00017
0.22 ± 0.17 0.22
1.05 ± 1.56 0.045
3.07 ± 1.36 0.027
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500 ng of genomic DNA was bisulfite treated using the
EZ DNA Methylation kit (Zymo Research, Orange,
CA, USA). DNA methylation analysis was performed
with EpiTYPER using Sequenom MassARRAY system
(Sequenom, Inc., San Diego, CA, USA) as previously de-
scribed [11]. Two EpiTYPER assays were designed using
the online EpiDesigner tool [20], covering a total of 18
CpG sites in the region upstream or downstream of the
transcription start site of the GLP1R gene. Primer infor-
mation is given in Additional file 1: Table S1. Due to ei-
ther high or low mass of the cleavage product, no data
was generated for 6 CpG sites. Because of the base spe-
cific cleavage of the EpiTYPER method, two CpG sites
positioned downstream of the transcription start site of
the GLP1R gene were analysed as a unit and therefore
called CpG site +199/+205.
Statistical analysis
Statistical analyses were performed using PASW Statis-
tics 18 for Windows (SPSS, Chicago, IL, USA). Non-
parametric two samples test, Mann–Whitney U test,
was performed to analyse differences between type 2
diabetes and non-diabetic donors. Correlations were
analysed using the non-parametric Spearman correl-
ation using all individuals in the study. Paired samples
t-test was used to analyse the difference in methylation
between α and β cells. The p-values presented in this
study have not been corrected for multiple testing. All
data is presented as mean ± sd and data in figures as
mean ± SEM.
Results
Pancreatic islets from 55 non-diabetic and 10 type 2 dia-
betic human donors were analysed in this study. Donor
characteristics are described in Table 1. Pancreatic islets
from type 2 diabetic organ donors showed a decrease in
glucose-stimulated insulin secretion compared with is-
lets from non-diabetic donors. In agreement with previ-
ous studies [14,16], we found that GLP1R expression
was reduced in pancreatic islets from donors diagnosed
with type 2 diabetes compared with non-diabetic donors
(type 2 diabetic 213±76.6 vs. non-diabetic 390.4±170.2,
p=0.0006). Furthermore, GLP1R mRNA expression in
the human islets correlated positively with the stimula-
tion index (SI) of glucose-stimulated insulin secretion
(Table 1) (rho=0.33, p=0.015). We next quantified DNA
methylation levels of 12 CpG sites of the GLP1R gene,
including 5 CpG sites upstream of and 7 CpG sites
downstream of the transcription start site (Figure 1A).
Two of the studied CpG sites, +199 and +205 bp from
the transcription start site, were analysed as a CpG unit,
due to the sequence characteristic of GLP1R. The majority
of the analysed CpG sites displayed a degree of DNAmethylation below 10% (Additional file 2: Table S2). The
CpG unit including CpG sites +199 and +205 showed in-
creased DNA methylation in islets from donors with type 2
diabetes compared with non-diabetic donors (Figure 1B).
However, the observed difference was small (0.53%, p=0.02)
and did not persist after correction for multiple testing. Be-
cause previous studies have shown that increased DNA
methylation may be associated with decreased gene ex-
pression [21], we next examined if DNA methylation of
GLP1R correlates with its gene expression in the human
islets. The CpG site located 376 bp upstream of the tran-
scription start site showed negative correlation with
GLP1R expression (rho=−0.34, p=0.008) (Figure 2A). In
addition, the same CpG site at position −376 correlated
positively with both BMI (rho=0.30, p=0.02) and HbA1c
levels (rho=0.30, p=0.03) (Figure 2B and C). There were
no significant correlations between the degree of DNA
methylation of the CpG unit including CpG sites +199
and +205 and GLP1R mRNA expression, BMI or
HbA1c levels (p>0.05). Neither did DNA methylation of
the other analysed CpG sites correlate negatively with
GLP1R mRNA expression or positively with BMI and
HbA1c levels (p>0.05). Transcription factor binding sites
around position −376 were queried in silico with a web-
based tool, TFsearch [22]. CpG site −376 is located in a
putative SP1 transcription factor binding site as marked
in Figure 1A.
Moreover, since it has been shown that GLP1R mainly
is expressed in β cells of pancreatic islets [6], we tested if
DNA methylation of the GLP1R promoter differed in α
and β cells isolated from three human pancreatic islet
donors. We found a significant increase in DNA methy-
lation of CpG site −376 in α cells compared with β cells
(α cells 14±5 vs. β cells 8±4, p=0.009) (Figure 3). How-
ever, there were no differences in DNA methylation be-
tween α and β cells for the other analysed CpG sites
(Additional file 3: Table S3).
Finally, we tested if the methyl binding protein MECP2,
which is known to control gene expression through the
interaction with transcriptional repressors [7], as well as
three DNA methyl transferases; DNMT1, DNMT3A and
DNMT3B, show differential expression in pancreatic islets
from patients with type 2 diabetes. There were no differ-
ences in MECP2, DNMT1 and DNMT3B expression be-
tween diabetic and non-diabetic donors (Figure 4A, B, D).
However, there was a trend towards decreased expression
of DNMT3A (p=0.056) in diabetic versus non-diabetic islets
(Figure 4C).
Discussion
A number of studies have shown differential DNA methy-
lation of a number of type 2 diabetic candidate genes in
human pancreatic islets pointing to a potential role of DNA
methylation in the pathogenesis of the disease [8,11-
BA
Figure 1 CpG sites analysed in this study and DNA methylation difference of CpG site +199/+205. A) Schematic figure showing the CpG
sites in regions upstream and downstream of transcription start site (marked with an arrow and +1) of the GLP1R gene analysed in this study. The
positions of the specific CpG sites are indicated in relationship to the transcription start site. One previously known transcription factor binding
site that co-localises with CpG site −376 is indicated above the specific CpG site. CpG sites +199 and +205 were analysed as a unit, which is
marked with brackets. B) The degree of DNA methylation of CpG site +199/+205 in non-diabetic and type 2 diabetic islets. Data are expressed as




Figure 2 DNA methylation of CpG site -376 correlates negatively with GLP1R expression and positively with BMI and HbA1c levels.
Correlation between the degree of DNA methylation of CpG site −376 of the GLP1R gene in pancreatic islets and A) GLP1R mRNA expression,
B) BMI and C) HbA1c levels in all individuals of the studied cohort.
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Figure 3 The degree of DNA methylation of CpG site −376 of the
GLP1R gene in α and β cells from pancreatic islets from three
human donors. Data are expressed as mean ± SEM. (** p<0.01).
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tion of a CpG site located 376 bp upstream from the tran-
scription start site in the promoter of GLP1R may affect the
expression of this gene. We found an inverse correlation
between DNA methylation of this CpG site and GLP1R
gene expression, suggesting that methylation of this specific
CpG site could have a negative effect on GLP1R gene ex-
pression. Wildhage et al. have reported that the GLP1R pro-
moter contains at least three SP1 binding sites which SP1
can bind to. The related transcription factor SP3 can bind
to only one of the sites [25]. CpG −376 is located in the
binding site to which both SP1 and SP3 can bind. WhileFigure 4 MECP2, DNMT1, DNMT3A and DNMT3B expression in human
C) DNMT3A and D) DNMT3B in pancreatic islets of human non-diabetic andSP1 in most cases serves as a transcriptional activator, SP3
has been reported to act as both an activator and as a re-
pressor, depending on cell and tissue type. The role of SP3
in regulating gene expression depends on several different
factors, including relative levels of SP1 and SP3, the num-
ber of SP1 binding sites in a promoter, cell and/or tissue
type, interaction with other proteins, and chemical modifi-
cation of the transcription factor. [26] Increased DNA
methylation of promoter regions is associated with tran-
scriptional silencing [21], either through preventing the
binding of specific transcription factors or through recruit-
ment of methyl CpG binding proteins, e.g. MeCP2, that
promote recruitment of histone deacetyltransferases and/or
co-repressors. DNA methylation of CpG −376 could poten-
tially repress the binding of SP1 to the GLP1R promoter
and hence result in transcriptional silencing. However, add-
itional functional studies are required to examine the spe-
cific role of GLP1R DNA methylation on gene
transcription.
It has previously been established that both protein and
mRNA expression of GLP1R is reduced in islets from pa-
tients with type 2 diabetes compared with non-diabetic con-
trols [14,16] as well as in rodent islets exposed to
hyperglycaemia [15]. Our study identified one CpG site
showing a small increase in GLP1R DNA methylation in is-
lets from type 2 diabetes patients. However, the GLP1R pro-
moter is highly GC rich making assay design for DNA
methylation analysis in large parts of the GLP1R promoter
inaccessible for analysis due to the requirement for CpG-freepancreatic islets. Gene expression of A) MECP2, B) DNMT1,
type 2 diabetic donors. Data are expressed as mean ± SEM.
Hall et al. BMC Medical Genetics 2013, 14:76 Page 6 of 7
http://www.biomedcentral.com/1471-2350/14/76primers when using standard techniques e.g. EpiTYPER or
Pyrosequencing. Hence, we cannot exclude that other areas
of the GLP1R may also show differential DNA methylation
in type 2 diabetes islets.
Hyperglycaemia, a high fat diet and obesity have previ-
ously been associated with differential DNA methylation in
target tissues for type 2 diabetes such as pancreatic islets,
skeletal muscle and liver [11,13,27-30]. For instance, HbA1c
has been shown to correlate positively with DNA methyla-
tion of INS and PDX-1 in human pancreatic islets and
hyperglycaemia was associated with increased DNA methy-
lation of the same genes in clonal β cells cultured in vitro.
Based on the positive correlations between both HbA1c and
BMI and DNA methylation of CpG site −376, the present
study suggests that hyperglycaemia and/or obesity may
affect DNA methylation of GLP1R in human islets. Interes-
tingly, hyperglycaemia has previously been shown to in-
crease the expression of a methyl transferase, Dnmt1, in
clonal β cells [13]. Elevated levels of this methyl transferase
may be a mechanism behind glucose induced DNA methy-
lation. However, we did not find any significant mRNA ex-
pression differences of DNMT1, DNMT3A and DNMT3B
in pancreatic islets from patients with type 2 diabetes. There
was a trend towards a decreased expression of DNMT3A in
type 2 diabetics compared with non-diabetics, but the diffe-
rence was small and not significant (200.8±13.8 and 212.7
±19.1 respectively, p=0.056). It is further possible that the
levels of methyl donors affect the degree of DNA methylation
in diabetic patients. Indeed, the level of S-adenosylmethionine,
a methyl group donor, has been reported to be decreased
in the erythrocytes of patients with type 2 diabetes [31].
Conclusion
Overall, our data suggest that DNA methylation influ-
ences gene expression of GLP1R in human pancreatic is-
lets. Decreased binding of the transcription factors SP1
and SP3 due to increased methylation may be involved
in reducing GLP1R expression. Furthermore, reduced
islet GLP1R levels associate with lower insulin secretion,
which is seen in patients with type 2 diabetes. The re-
sults of this study again indicate that epigenetic me-
chanisms may contribute to type 2 diabetes, however
additional studies are needed to fully understand the
mechanisms involved in this regulation.Additional files
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